Home › Breast Cancer › NCT07426913
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * 18 years of age or older * Able to speak and read in English * Actively receiving Trastuzumab or an anthracycline-based treatment * Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab. * Diagnosed with stages 0-III Breast Cancer Exclusion Criteria: \- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)
About the study
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).
What is being tested
- Cardiovascular Health Education and Gaming through Virtual Reality (behavioral)
Sponsor: Virginia Commonwealth University · Participants: 30 · Started: May 20, 2026
Contact the study team
- Arnethea Sutton, Ph.D · Phone: 8048277363
- Victoria Williams · Phone: 8048277363
Official record on ClinicalTrials.gov — NCT07426913
Locations in the U.S.
| Virginia | Adult Outpatient Pavilion, Richmond Cellular Immunotherapies and Transplant Department, Richmond VCU Health at Stony Point, Richmond |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.